Cover Image
Market Research Report
Product code
1017685

Tyrosine Protein Kinase Mer - Drugs In Development, 2021

Published: | Global Markets Direct | 94 Pages | Delivery time: 1-2 business days

Price

Back to Top
Tyrosine Protein Kinase Mer - Drugs In Development, 2021
Published: June 30, 2021
Global Markets Direct
Content info: 94 Pages
Delivery time: 1-2 business days
  • ALL
  • Description
  • Table of Contents
Description

Summary:

According to the recently published report 'Tyrosine Protein Kinase Mer - Drugs In Development, 2021'; Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) pipeline Target constitutes close to 19 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes.

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Proto-oncogene tyrosine-protein kinase MER is an enzyme encoded by the MERTK gene. It regulates many physiological processes including cell survival, migration, differentiation, and phagocytosis of apoptotic cells. It plays a role in various processes such as macrophage clearance of apoptotic cells, platelet aggregation, cytoskeleton reorganization and engulfment. Functions in the retinal pigment epithelium (RPE) as a regulator of rod outer segments fragments phagocytosis. It also plays an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response by activating STAT1.

The report 'Tyrosine Protein Kinase Mer - Drugs In Development, 2021' outlays comprehensive information on the Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 4, 9 and 1 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Report covers products from therapy areas Oncology and Ophthalmology which include indications Non-Small Cell Lung Cancer, Solid Tumor, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Gastric Cancer, Triple-Negative Breast Cancer (TNBC), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Gallbladder Cancer, Glioblastoma Multiforme (GBM), Lung Cancer, Melanoma, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Melanoma, Ovarian Cancer, Renal Cell Carcinoma, Soft Tissue Sarcoma, Adenocarcinoma Of The Gastroesophageal Junction, Bladder Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colon Cancer, Colorectal Cancer, Epithelial Ovarian Cancer, Gastroesophageal (GE) Junction Carcinomas, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Hepatocellular Carcinoma, Kidney Cancer (Renal Cell Cancer), Liposarcoma, Mantle Cell Lymphoma, Metastatic Biliary Tract Cancer, Metastatic Colorectal Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Myelodysplastic Syndrome, Non-Hodgkin Lymphoma, Oral Cavity (Mouth) Cancer, Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Retinitis Pigmentosa (Retinitis), Rhabdomyosarcoma, Squamous Non-Small Cell Lung Cancer, Synovial Sarcoma and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1)
  • The report reviews Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Product Code: GMDHC2873TDB

Table of Contents

Table of Contents

  • Introduction
  • Global Markets Direct Report Coverage
  • Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Overview
  • Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Companies Involved in Therapeutics Development
  • Celldex Therapeutics Inc
  • Celon Pharma SA
  • Dong-A Socio Holdings Co Ltd
  • Eli Lilly and Co
  • F. Hoffmann-La Roche Ltd
  • HEC Pharma Co Ltd
  • Hope Biosciences Inc
  • Incyte Corp
  • Mediolanum farmaceutici SpA
  • Meryx Inc
  • Mirati Therapeutics Inc
  • Ono Pharmaceutical Co Ltd
  • Pfizer Inc
  • Qurient Co Ltd
  • Rgenix Inc
  • SignalChem Lifesciences Corp
  • Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Drug Profiles
  • CDX-0168 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CT-413 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • DA-4501 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ELB-031 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Activate MERTK for Retinitis Pigmentosa - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HOPE-777 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • INCB-81776 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Mer-590 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • merestinib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MRX-2843 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MRX-6313 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ONO-7475 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PF-07265807 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Q-702 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RGX-019 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RXDX-106 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • sitravatinib malate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit Mer Tyrosine Kinase for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit MERTK for Hematological and Solid Tumors - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Dormant Products
  • Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Discontinued Products
  • Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Product Development Milestones
  • Featured News & Press Releases
  • Apr 11, 2021: BeiGene presents clinical data on Sitravatinib in combination with Tislelizumab at the AACR Annual Meeting 2021
  • Mar 10, 2021: BeiGene announces presentation of clinical data on Sitravatinib in combination with tislelizumab at the AACR Annual Meeting 2021
  • Jan 26, 2021: Qurient enrolls first patient in Q702 U.S. phase 1 study
  • Sep 18, 2020: Mirati Therapeutics presents phase 2 data on sitravatinib in combination with nivolumab in urothelial cancer At ESMO Virtual Congress
  • Jun 22, 2020: RGENIX presents results from preclinical safety and efficacy studies of RGX-019 at the 2020 AACR Annual Meeting
  • May 26, 2020: Qurient announces U.S. FDA clearance of IND application for Q702, a novel cancer immunotherapy
  • Feb 15, 2020: Mirati Therapeutics announces initial data in Renal Cell Carcinoma from ongoing investigator sponsored clinical trial Of Sitravatinib in combination With Nivolumab at The 2020 ASCO Genitourinary Cancers Syposium
  • Dec 13, 2019: Sitravatinib plus Tislelizumab show promise in platinum-resistant advanced ovarian cancer
  • Nov 09, 2019: Mirati Therapeutics Presents Data From Ongoing Clinical Trials Of Sitravatinib In Combination With Nivolumab At The SITC 34th Annual Meeting
  • Oct 23, 2019: Mirati Therapeutics announces presentation of interim phase 2 Sitravatinib data In Urothelial Carcinoma and Oral Cavity Squamous Cell Carcinoma At The SITC 34th Annual Meeting
  • Apr 08, 2019: Dong-A ST's investigational drug posts positive study results
  • Apr 03, 2019: Rgenix presents pre-clinical data on RGX-019 at the 2019 AACR Annual Meeting
  • Apr 01, 2019: Rgenix to present abstract on RGX-019 at the 2019 AACR Annual Meeting
  • Nov 23, 2018: Mirati Therapeutics joins Cancer Research UK's Stratified Medicine Programme
  • Nov 10, 2018: Celldex presents emerging MerTK antibody program at the Society for Immunotherapy of Cancer's 33rd annual meeting
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

List of Tables

  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Indications, 2021
  • Number of Products under Development by Indications, 2021 (Contd..1)
  • Number of Products under Development by Indications, 2021 (Contd..2)
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Companies, 2021 (Contd..1)
  • Products under Development by Companies, 2021 (Contd..2)
  • Products under Development by Companies, 2021 (Contd..3)
  • Products under Development by Companies, 2021 (Contd..4)
  • Number of Products under Investigation by Universities/Institutes, 2021
  • Products under Investigation by Universities/Institutes, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Pipeline by Celldex Therapeutics Inc, 2021
  • Pipeline by Celon Pharma SA, 2021
  • Pipeline by Dong-A Socio Holdings Co Ltd, 2021
  • Pipeline by Eli Lilly and Co, 2021
  • Pipeline by F. Hoffmann-La Roche Ltd, 2021
  • Pipeline by HEC Pharma Co Ltd, 2021
  • Pipeline by Hope Biosciences Inc, 2021
  • Pipeline by Incyte Corp, 2021
  • Pipeline by Mediolanum farmaceutici SpA, 2021
  • Pipeline by Meryx Inc, 2021
  • Pipeline by Mirati Therapeutics Inc, 2021
  • Pipeline by Ono Pharmaceutical Co Ltd, 2021
  • Pipeline by Pfizer Inc, 2021
  • Pipeline by Qurient Co Ltd, 2021
  • Pipeline by Rgenix Inc, 2021
  • Pipeline by SignalChem Lifesciences Corp, 2021
  • Dormant Products, 2021
  • Dormant Products, 2021 (Contd..1)
  • Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Top 10 Indications, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021